1. Home
  2. ASC vs PRTC Comparison

ASC vs PRTC Comparison

Compare ASC & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ASC

Ardmore Shipping Corporation

HOLD

Current Price

$13.67

Market Cap

508.7M

ML Signal

HOLD

Logo PureTech Health plc

PRTC

PureTech Health plc

N/A

Current Price

$16.64

Market Cap

464.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ASC
PRTC
Founded
2010
2015
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
508.7M
464.3M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
ASC
PRTC
Price
$13.67
$16.64
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$15.00
N/A
AVG Volume (30 Days)
852.6K
4.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
2.20%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$16.60
$8.09
Revenue Growth
N/A
N/A
52 Week Low
$8.32
$13.30
52 Week High
$16.91
$20.00

Technical Indicators

Market Signals
Indicator
ASC
PRTC
Relative Strength Index (RSI) 38.62 42.95
Support Level $10.42 $16.51
Resistance Level $16.91 $18.10
Average True Range (ATR) 0.62 0.53
MACD -0.35 -0.06
Stochastic Oscillator 6.58 13.87

Price Performance

Historical Comparison
ASC
PRTC

About ASC Ardmore Shipping Corporation

Ardmore Shipping Corp provides seaborne transportation of petroleum products and chemicals world-wide to oil majors, national oil companies, oil and chemical traders, and chemical companies, with its modern, fuel-efficient fleet of mid-size product and chemical tankers. The Company operates its business in one operating segment, the transportation of refined petroleum products and chemicals.

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

Share on Social Networks: